Company Overview - The company, Yinhang Biotechnology, is a leader in synthetic biology driven by technological innovation, focusing on providing green, sustainable, and cost-effective bio-based products [2] - The company has established a leading market position in the production of active pharmaceutical ingredients (APIs) and intermediates, with a 24.5% market share in the global florfenicol industry and a 44.5% market share in the D-ethyl market as of the nine months ending September 30, 2025 [2] Research and Development - Yinhang Biotechnology has developed a "dual-engine" R&D capability, which includes breakthrough original process design and AI-assisted high-throughput DBTL workflows for efficient synthetic biology engineering [2][3] - The company has built two production bases for large-scale industrialization, which is crucial for rapid commercialization and achieving a leading market position [3] Financial Performance - The company reported revenues of approximately RMB 298 million for the fiscal year 2023, RMB 345 million for 2024, RMB 249 million for the nine months ending September 30, 2024, and RMB 380 million for the nine months ending September 30, 2025 [4] - The gross profit figures for the same periods were approximately RMB 33.6 million, -RMB 37.1 million, -RMB 20.1 million, and RMB 5.6 million respectively, indicating fluctuations in profitability [5][8] Market Trends - The global synthetic biology market is projected to grow from USD 21.5 billion in 2024 to USD 99.6 billion by 2030, with a compound annual growth rate (CAGR) of 23.2% from 2024 to 2035 [10] - The global market for APIs and intermediates is expected to increase from USD 256.8 billion in 2024 to USD 347.7 billion by 2030, with a CAGR of 4.7% from 2024 to 2035 [12] - The D-ethyl market is anticipated to grow from USD 80.1 million in 2024 to USD 130.1 million by 2030, with a CAGR of 9.1% from 2024 to 2035 [15]
新股消息 | 引航生物递表港交所 位居全球氟苯尼考行业第二位
智通财经网·2026-02-12 23:05